Replies to post #32510 on Cel Sci Corporation (CVM)

[GD]

You are right, NWBO is trying to find subgroup data
with bio-markers to prove DCVax®-L works, I think
DCVax®-L PIII is really messed-up with the PSF
primary end point and high % cross-over from placebo
arm on secondary OS endpoint, IMO. NWBO is trying very hard
with FDA to write a new SAP, so far NWBO has not PR
any agreements with FDA yet, from DNDN's experiences,
NWBO is going to have a very hard time asking FDA approval
with any subgroup efficacy, I used to own 1.55M shares
of NWBO, when NWBO say they are going to write a new
SAP, I sold out, but watching on the side line to the
end for a good lesson.